Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06513507 · ClinicalTrials.gov registry record · NA
A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.
A NA study of Rheumatoid Arthritis and Inflammatory Disease, sponsored by Raphael Pharma.
- Active
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06513507: Active NA study of Rheumatoid Arthritis and Inflammatory Disease, sponsored by Raphael Pharma.
NCT06513507 is a NA study of Rheumatoid Arthritis and Inflammatory Disease that is active but no longer recruiting, run by Raphael Pharma. The registered enrollment target is 12 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06513507, a NA study of Rheumatoid Arthritis and Inflammatory Disease, is active but no longer recruiting, sponsored by Raphael Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.
Primary Outcome
Measurement of blood levels of ESR (Erythrocyte Sedimentation Rate), CRP (C-Reactive Protein), IL6 (Interleukin 6), and TNFa (Tumor Necrosis Factor-alpha) at Baseline, Week 2, Week 4, Week 6, and Week 8.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Cannabigerol (CBG)
Study Locations (1)
California
- Citruslabs - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
What the registry record for NCT06513507 still lists
NCT06513507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Cannabigerol (CBG) is the first listed.
NCT06513507 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06513507 about?
NCT06513507 is a clinical study titled "A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.". This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.
What is the current status of trial NCT06513507?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2024-06-03. Estimated completion is 2024-12-31.
What conditions does trial NCT06513507 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis, Inflammatory Disease.
What interventions are being tested in trial NCT06513507?
The interventions under investigation include: Cannabigerol (CBG) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06513507?
This trial is sponsored by Raphael Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06513507 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06513507's enrollment target sits among peer trials
12 195th of 197 higher than 2 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis
RECRUITING · NA
-
Improving Hypertension Control in Rheumatoid Arthritis
RECRUITING · NA
-
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI